Ulla Mandel

Ulla Mandel

Auto-generated profile, based on publicly available information

Ulla Mandel

Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CSCatharina Steentoft
Catharina Steentoft
SVSergey Vakhrushev
Sergey Vakhrushev
HJHiren J Joshi
Hiren J Joshi
YKYun Kong
Yun Kong
MVMalene B Vester‐Christensen
Malene B Vester‐Christensen
HCHenrik Clausen
Henrik Clausen
Glycosylation is the most abundant and diverse posttranslational modification of proteins. While several types of glycosylation can be predicted by the protein sequence context, and substantial knowledge of these glycoproteomes is available, our knowledge of the GalNAc‐type O ‐glycosylation is highly limited. This type of glycosylation is unique in being regulated by 20 polypeptide GalNAc‐transferases attaching the initiating GalNAc monosaccharides to Ser and Thr (and likely some Tyr) residues. We have developed a genetic engineering approach using human cell lines to simplify O ‐glycosylation (SimpleCells) that enables proteome‐wide discovery of O ‐glycan sites using ‘bottom‐up’ ETD‐based mass spectrometric analysis. We implemented this on 12 human cell lines from different organs, and present a first map of the human O ‐glycoproteome with almost 3000 glycosites in over 600 O ‐glycoproteins as well as an improved NetOGlyc4.0 model for prediction of O ‐glycosylation. The finding of unique subsets of O ‐glycoproteins in each cell line provides evidence that the O ‐glycoproteome is differentially regulated and dynamic. The greatly expanded view of the O ‐glycoproteome should facilitate the exploration of how site‐specific O ‐glycosylation regulates protein function.

18 December 2011 in Glycobiology
Verified
Journal Article
Closed access
EBE. P. Bennett
E. P. Bennett
UMU. Mandel
U. Mandel
HCH. Clausen
H. Clausen
TGT. A. Gerken
T. A. Gerken
TFT. A. Fritz
T. A. Fritz
LTL. A. Tabak
L. A. Tabak
Glycosylation of proteins is an essential process in all eukaryotes and a great diversity in types of protein glycosylation exists in animals, plants and microorganisms. Mucin-type O-glycosylation, consisting of glycans attached via O-linked N-acetylgalactosamine (GalNAc) to serine and threonine residues, is one of the most abundant forms of protein glycosylation in animals. Although most protein glycosylation is controlled by one or two genes encoding the enzymes responsible for the initiation of glycosylation, i.e. the step where the first glycan is attached to the relevant amino acid residue in the protein, mucin-type O-glycosylation is controlled by a large family of up to 20 homologous genes encoding UDP-GalNAc:polypeptide GalNAc-transferases (GalNAc-Ts) (EC 2.4.1.41). Therefore, mucin-type O-glycosylation has the greatest potential for differential regulation in cells and tissues. The GalNAc-T family is the largest glycosyltransferase enzyme family covering a single known glycosidic linkage and it is highly conserved throughout animal evolution, although absent in bacteria, yeast and plants. Emerging studies have shown that the large number of genes (GALNTs) in the GalNAc-T family do not provide full functional redundancy and single GalNAc-T genes have been shown to be important in both animals and human. Here, we present an overview of the GalNAc-T gene family in animals and propose a classification of the genes into subfamilies, which appear to be conserved in evolution structurally as well as functionally.

1 June 2016 in Immunity
Verified
Journal Article
Closed access
Avery Posey, Jr.Avery Posey, Jr.
Avery Posey, Jr.
RSRobert D. Schwab
Robert D. Schwab
ABAlina C. Boesteanu
Alina C. Boesteanu
CSCatharina Steentoft
Catharina Steentoft
UMUlla Mandel
Ulla Mandel
CJCarl H. June
Carl H. June

9 October 2011 in Nature Methods
Verified
Journal Article
Closed access
CSCatharina Steentoft
Catharina Steentoft
SVSergey Vakhrushev
Sergey Vakhrushev
MVMalene B Vester-Christensen
Malene B Vester-Christensen
KSKatrine T-B G Schjoldager
Katrine T-B G Schjoldager
YKYun Kong
Yun Kong
HCHenrik Clausen
Henrik Clausen

1 July 2019 in Molecular Cell
Verified
Journal Article
Closed access
YNYoshiki Narimatsu
Yoshiki Narimatsu
HJHiren J. Joshi
Hiren J. Joshi
RNRebecca Nason
Rebecca Nason
JCJulie Van Coillie
Julie Van Coillie
RKRichard Karlsson
Richard Karlsson
HCHenrik Clausen
Henrik Clausen

18 October 2006 in Glycobiology
Verified
Journal Article
Open access
PDF file
MTMads A. Tarp
Mads A. Tarp
ASAnne Louise Sørensen
Anne Louise Sørensen
UMUlla Mandel
Ulla Mandel
HPHans Paulsen
Hans Paulsen
JBJoy Burchell
Joy Burchell
HCHenrik Clausen
Henrik Clausen
The cell membrane mucin MUC1 is over-expressed and aberrantly glycosylated in many cancers, and cancer-associated MUC1 glycoforms represent potential targets for immunodiagnostic and therapeutic measures. We have recently shown that MUC1 with GalNAcα1-O-Ser/Thr (Tn) and NeuAcα2-6GalNAcα1-O-Ser/Thr (STn) O-glycosylation is a cancer-specific glycoform, and that Tn/STn-MUC1 glycopeptide-based vaccines can override tolerance in human MUC1 transgenic mice and induce humoral immunity with high specificity for MUC1 cancer-specific glycoforms (Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, et al. 2006. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 16:96–107). In order to further characterize the immune response to Tn/STn-MUC1 glycoforms, we generated monoclonal antibodies with specificity similar to the polyclonal antibody response found in transgenic mice. In the present study, we define the immunodominant epitope on Tn/STn-MUC1 glycopeptides to the region including the amino acids GSTA of the MUC1 20-amino acid tandem repeat (HGVTSAPDTRPAPGSTAPPA). Most other MUC1 antibodies are directed to the PDTR region, although patients with antibodies to the GSTA region have been identified. A panel of other MUC1 glycoform-specific monoclonal antibodies was included for comparison. The study demonstrates that the GSTA region of the MUC1 tandem repeat contains a highly immunodominant epitope when presented with immature short O-glycans. The cancer-specific expression of this glycopeptide epitope makes it a prime candidate for immunodiagnostic and therapeutic measures.